Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial - Quiz - MDSpire

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

  • By

  • Ghazaleh Tabatabai

  • Isabel Ramirez

  • Beatrix Welte

  • Paula Bombach

  • Hannes Becker

  • Denise Bernhardt

  • Regine Mayer-Steinacker

  • Friedegund Meier

  • Nicolas Neidert

  • Roland Roelz

  • Iris Mildenberger

  • Lukas Bunse

  • Michael Platten

  • Ulrich Herrlinger

  • Uwe M. Martens

  • Ulrike Ernemann

  • Manuela Neumann

  • Marcos Tatagiba

  • Lina Maria Serna-Higuita

  • Peter Martus

  • Mirjam Renovanz

  • June 4, 2026

  • 0 min

Share

Original Source(s)

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

  • by Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, Paula Bombach, Hannes Becker, Denise Bernhardt, Regine Mayer-Steinacker, Friedegund Meier, Nicolas Neidert, Roland Roelz, Iris Mildenberger, Lukas Bunse, Michael Platten, Ulrich Herrlinger, Uwe M. Martens, Ulrike Ernemann, Manuela Neumann, Marcos Tatagiba, Lina Maria Serna-Higuita, Peter Martus, Mirjam Renovanz

  • June 4, 2026

Related Content

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review